Effect of albumin with Standard Treatment in Liver Cirrhosis (Liver Disease)
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2020/11/028986
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1) Patients with cirrhosis of liver with recurrent ascites.
2) Patients with age from 18-70 years
1.Renal failure (Creatinine >1.5mg/dl)
2.Recent Gastrointestinal bleeding within 7 days
3.Spontaneous bacterial Peritonitis
4.Patients with organic nephropathy ( as defined by IAC)
5.Patients with Cardiovascular disease or chronic obstructive pulmonary disease
6.Systemic arterial hypertension ( >160/90mmhg)
7.Presence of hepatocellular carcinoma (outside Milan criteria)( or portal vein thrombosis
8.Budd-Chiari Syndrome
9.Patients with active sepsis
10.Pregnancy
11.Patients with hepatic encephalopathy
12.No use of drugs affecting systemic hemodynamics 7 days prior to enrolment (except beta-blockers)
13.Patients with serum albumin >3 gm
14.Refusal to participate
15.Known or suspected hypersensitivity to albumin
16.Prior TIPS
17.Post liver or kidney transplantation
18.Patients enrolled in other clinical trials
19.Extrahepatic malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method